e-learning
resources
Virtual 2020
Pre-Congress Content
Air pollution and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LSC - 2020 - Could the overweight influence bronchiectasis (B) exacerbations frequency (EF)?
K. Suska (Dnipro, Ukraine), K. Gashynova (Dnipro, Ukraine), V. Dmytrychenko (Dnipro, Ukraine)
Source:
Virtual Congress 2020 – Air pollution and comorbidities
Session:
Air pollution and comorbidities
Session type:
E-poster session
Number:
128
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Suska (Dnipro, Ukraine), K. Gashynova (Dnipro, Ukraine), V. Dmytrychenko (Dnipro, Ukraine). LSC - 2020 - Could the overweight influence bronchiectasis (B) exacerbations frequency (EF)?. 128
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples
Source: Eur Respir J 2005; 26: Suppl. 49, 595s
Year: 2005
Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
LSC - 2020 - The lung DNA methylation profile of patients with COPD: relationship with smoking and airflow limitation severity.
Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies
Year: 2020
Late Breaking Abstract - The population attributable risks (PAR) for chronic airflow obstruction (CAO) in 40 BOLD study centres worldwide.
Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections
Year: 2018
CAT in COPD phenotypes (POPE study)
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Influence of cigarette smoking (CS) on the pulmonary complaints (PC), function of the external breathing (FEB) and quality of life (QL) in the practically healthy persons
Source: Eur Respir J 2007; 30: Suppl. 51, 165s
Year: 2007
COPD (C) and asthma (A) comorbidities in Italian primary care
Source: Annual Congress 2010 - Comorbidity in obstructive airway disease
Year: 2010
Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012
How does regular exercise affect dyspnoe (TDI) and quality of life (CAT) of COPD-patients 1 year after an inpatient pulmonary rehabilitation (PR)?
Source: International Congress 2015 – Latest insights into pulmonary rehabilitation
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept